| Background | Rituximab (Rituxan) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with certain autoimmune diseases and types of cancer, such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, idiopathic thrombocytopenic purpura, and pemphigus vulgaris. Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. When it binds to this protein it triggers cell death.
• Induction Immunosuppression in High-risk Kidney Transplant Recipients., PMID:27041548
• Acute Rejection Following Kidney Transplantation: State-of-the-Art and Future Perspectives., PMID:32520680
• Induction immunosuppressive therapies in renal transplantation., PMID:21258026
• Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production., PMID:18976291
• Removal of therapeutic anti-lymphocyte antibodies from human sera prior to anti-human leukocyte antibody testing., PMID:15896799
• [Biological treatment following renal transplantation]., PMID:21877601
• Role of RLIP76 in lung cancer doxorubicin resistance: III. Anti-RLIP76 antibodies trigger apoptosis in lung cancer cells and synergistically increase doxorubicin cytotoxicity., PMID:12632061
• Flow cytometric assay detecting cytotoxicity against human endogenous retrovirus antigens expressed on cultured multiple sclerosis cells., PMID:23656307
• Life-threatening hemolytic anemia due to an autoanti-Pr cold agglutinin: evidence that glycophorin A antibodies may induce lipid bilayer exposure and cation permeability independent of agglutination., PMID:19843291
|
|---|
